<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (MDSs) represent a group of incurable stem-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> which are predominantly treated by supportive care </plain></SENT>
<SENT sid="1" pm="."><plain>Epigenetic silencing through promoter methylation of a number of genes is present in poor-risk subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and often predicts transformation to <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> and <z:chebi fb="0" ids="50131">decitabine</z:chebi>, two FDA-approved DNA methyltransferase (DNMT) inhibitors, are able to improve overall response although their oral bioavailability complicates their clinical use </plain></SENT>
<SENT sid="3" pm="."><plain>This study evaluated 2', 3', 5'-triacetyl-5-<z:chebi fb="0" ids="2038">azacitidine</z:chebi> (<z:chebi fb="44" ids="53498">TAC</z:chebi>) as a potential <z:chebi fb="0" ids="50266">prodrug</z:chebi> for <z:chebi fb="0" ids="2038">azacitidine</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:chebi fb="0" ids="50266">prodrug</z:chebi> demonstrated significant pharmacokinetic improvements in bioavailability, solubility, and stability over the parent compound </plain></SENT>
<SENT sid="5" pm="."><plain>In vivo analyses indicated a lack of general toxicity coupled with significantly improved survival </plain></SENT>
<SENT sid="6" pm="."><plain>Pharmacodynamic analyses confirmed its ability to suppress global methylation in vivo </plain></SENT>
<SENT sid="7" pm="."><plain>These data indicate that esterified <z:chebi fb="0" ids="33838">nucleoside</z:chebi> derivatives may be effective <z:chebi fb="0" ids="50266">prodrugs</z:chebi> for <z:chebi fb="0" ids="2038">azacitidine</z:chebi> and encourages further investigation of <z:chebi fb="44" ids="53498">TAC</z:chebi> into its metabolism, activity, and possible clinical evaluation </plain></SENT>
</text></document>